標題
返回
確定
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Topics
Business
Business
PR Newswire
AI & Semiconductor
AI & Semiconductor
Taiwan
Taiwan
Politics
Defense
Life
China
China
World
World
Editorial
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
Abbisko Therapeutics
#
Abbisko Therapeutics
About 2 search results
Sort by Date
Business
PR Newswire
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
SHANGHAI
PR Newswire
2026-07-02 09:00
Lumipodlin
TAGRISSO
Abbisko Therapeutics
Business
PR Newswire
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
SHANGHAI
PR Newswire
2026-06-24 09:00
Abbisko Therapeutics
Eli Lilly
R&D collaboration